About this trial
The goal of this clinical trial is to evaluate whether implementation of guideline-recommended Automated Office Blood Pressure (AOBP) measurement in Australian general practice clinics improves hypertension control among adults aged 18 years and older who are eligible for blood pressure assessment as part of routine clinical care. The study will also evaluate the implementation, sustainability, and health economic impact of AOBP in real-world primary care settings.
The main questions it aims to answer are:
* Does implementation of AOBP increase the proportion of patients with treated and controlled hypertension compared with the pre-implementation period? * Can AOBP be successfully adopted, implemented, integrated into routine general practice workflows, and maintained over time?
Researchers will compare outcomes following implementation of AOBP with routinely collected clinical data from the period before implementation.
Participants will:
* Provide informed consent and have their AOBP measurements performed during routine general practice visits. * Consent to the collection of AOBP measurement and relevant clinical information from their medical records for study evaluation. * Continue to receive usual clinical care from their general practitioner.
General practice staff will receive AOBP training, perform AOBP measurements, and participate in implementation evaluation activities.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adults aged 45 to 79 years without known CVD
Adults aged 35 to 79 years with diabetes and without known CVD
First Nations peoples aged 30 to 79 years without known CVD
First Nations peoples aged 18 to 29 years
Disqualifiers
Patients who are unable to provide informed consent.
Patients whose participation is deemed clinically inappropriate by the treating general practitioner.
Trial design
Single group
Treatments tested in this trial
Automated Office Blood Pressure (AOBP) Standardized Measurement Protocol
DeviceImplementation of a standardized AOBP measurement protocol using a validated automated sphygmomanometer. AOBP measurements will be conducted by trained general practice staff. Patients will be seated in a quiet area with back supported, feet flat on the floor, arm supported at heart level, and an appropriately sized cuff applied. Following a 5-minute automated rest period, the device automatically records three seated blood pressure measurements at 30-second intervals and a fourth brief measurement to detect arrhythmia/atrial fibrillation. The device automatically calculates and records the average of the three seated measurements, heart rate, and arrhythmia status. Where clinically indicated, a standing protocol will be performed following the seated protocol and consists of two standing blood pressure measurements recorded at 30-second intervals after 1 minute of standing, followed by an arrhythmia assessment. Results are provided to the treating general practitioner.
Treatment groups
Trial outcomes
Primary outcomes
The proportion of patients with treated and controlled hypertension, with the primary estimand being the absolute difference in this proportion between the pre-implementation period and 12-month AOBP implementation period.
Hypertension control will be defined according to Australian guideline recommendations using AOBP thresholds (average systolic BP \<135 mmHg and diastolic BP \<85 mmHg). "Treated" refers to patients receiving antihypertensive therapy.
Secondary outcomes
Average systolic and diastolic BP measured using AOBP
Heart rate recording during AOBP measurement
Frequency of repeat AOBP measures during the study period
Changes in systolic and diastolic blood pressure values over time, measured using AOBP
Other outcomes
Cardiovascular disease risk factors ascertained via data linkage
Obesity, hypertension, hyperlipidaemia, Type II diabetes mellitus, smoking status
Death
CVD death, all-cause mortality
Hospitalization ascertained via data linkage
Emergency department presentations, public hospital admissions, private hospital admissions
Cardiovascular disease events ascertained via data linkage
Including: angina, acute myocardial infarction, ischemic heart disease, cardiomyopathy, atrial fibrillation, hypertensive heart disease, heart failure, heart valve disease, presence of cardiac and vascular implants and grafts, cerebrovascular disease, peripheral artery disease, chronic kidney disease
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Menzies Institute for Medical Research
Lead sponsor
National Health and Medical Research Council, Australia
Collaborator
Hypertension Australia
Collaborator
Australian Cardiovascular Alliance
Collaborator
Pharmaceutical Society of Australia
Collaborator
Ochre Health
Collaborator
Uscom Limited
Collaborator
JA Davey
Collaborator
A&D Australasia
Collaborator
Servier Laboratories (Australia) Pty Ltd
Collaborator
National Heart Foundation, Australia
Collaborator
This trial is not recruiting at the moment. You can still explore other options: